STIFTUNG ELN FOUNDATION

Their core work

The ELN Foundation (European LeukemiaNet) is a Germany-based foundation dedicated to improving diagnosis, treatment, and outcomes for patients with hematological malignancies — blood cancers such as leukemia, lymphoma, myelodysplastic syndromes, and multiple myeloma. They contribute to large-scale EU research initiatives by providing clinical expertise, patient registries, and real-world data infrastructure for hematology and oncology research. Their work spans from molecular genetics and translational medicine to building big data platforms that capture real-life patient outcomes, enabling evidence-based treatment decisions across Europe.

What they specialise in

How they've shifted over time

The ELN Foundation's H2020 journey started in 2015 with focused clinical research on a specific blood disorder (MDS), then expanded significantly into large-scale data infrastructure with the HARMONY project (2017). By 2020, HARMONY PLUS shows a clear evolution toward sustainability — adding business models, digital health outcomes, and translational medicine to their portfolio. The trajectory moves from single-disease clinical focus toward pan-hematology data ecosystems with long-term viability.

Moving toward sustainable, digitally-enabled hematology data infrastructure with translational medicine applications — likely seeking partners who can help scale and commercialize medical data platforms.

How they like to work

The ELN Foundation exclusively participates as a partner, never leading as coordinator — consistent with their role as a specialized foundation contributing domain expertise to large collaborative efforts. With 67 unique consortium partners across 14 countries in just 3 projects, they operate in very large consortia (averaging 22+ partners per project). This suggests they are well-networked and trusted within the European hematology community, comfortable working within complex multi-partner structures.

With 67 unique partners across 14 countries from just 3 projects, the ELN Foundation sits at the center of Europe's hematology research network. Their consortia are large and geographically diverse, reflecting the pan-European nature of blood cancer research coordination.

What sets them apart

The ELN Foundation is not a university or hospital — it is a dedicated foundation for the European LeukemiaNet, giving it a unique convening role in hematology research across borders. Their combination of clinical hematology expertise with big data platform development makes them a rare bridge between the medical community and digital health infrastructure. For anyone building a consortium in blood cancer research or medical data analytics, the ELN Foundation brings both deep domain credibility and an established network of 67+ European partners.

Highlights from their portfolio

• HARMONY
  Largest project by funding (EUR 400K to ELN), flagship big data initiative in hematology with a massive consortium — the Healthcare Alliance for Resourceful Medicines Offensive against Neoplasms.
• HARMONY PLUS
  Continuation project that shifts focus toward sustainability, business models, and translational medicine — signals the foundation's strategic direction beyond EU funding cycles.
• MDS-RIGHT
  Earliest H2020 project (2015), focused specifically on myelodysplastic syndromes — demonstrates deep specialization before the broader hematology platform work.